Immunome, Inc.
- Open
- 27.60
- Day high
- 28.27
- Day low
- 26.93
- Prev close
- 27.33
- Volume
- 45K
- Mkt cap
- $3.1B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 5.9
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$15.7M over the last 3 months (3 open-market buys, 20 sales)
- 🏛Institutions reducing (13F)
Immunome, Inc. (IMNM) is a Healthcare company listed on NASDAQ. The stock is up 164% over the past year. Over the trailing 3 months, insiders filed 3 open-market buys and 20 sales (SEC Form 4).
Immunome, Inc. (IMNM) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
IMNM earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 11, 2026 | $-0.51 | $-0.65 | -26.5% | — | — |
| May 12, 2026 | $-0.60 | $-0.48 | +20.0% | — | — |
| Mar 3, 2026 | $-0.65 | $-0.75 | -15.4% | — | — |
| Nov 6, 2025 | $-0.57 | $-0.65 | -14.0% | — | — |
| Aug 6, 2025 | $-0.52 | $-0.50 | +3.8% | $4M | +381.8% |
| Mar 19, 2025 | $-0.68 | $-0.84 | -23.5% | $3M | -13.0% |
| Nov 9, 2023 | $-0.17 | $-0.36 | -111.8% | $4M | +0.0% |
| May 5, 2023 | $0.59 | $-0.35 | -159.3% | $2M | — |
| Mar 16, 2023 | $0.67 | $-0.64 | -195.5% | — | — |
| Nov 14, 2022 | $-0.76 | $-0.75 | +1.3% | — | — |
| Aug 5, 2022 | $-0.75 | $-0.74 | +1.3% | — | — |
| May 12, 2022 | $-0.69 | $-0.96 | -39.1% | — | — |
IMNM insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 12, 2026 | Barchas Isaacdirector | Sell | 10,125 | $26.07 |
| Aug 12, 2026 | Barchas Isaacdirector | Sell | 11,048 | $27.25 |
| Aug 12, 2026 | Barchas Isaacdirector | Sell | 62,291 | $26.23 |
| Aug 10, 2026 | Barchas Isaacdirector | Sell | 15,248 | $26.06 |
| Aug 10, 2026 | Barchas Isaacdirector | Sell | 20,840 | $26.06 |
| Aug 6, 2026 | Horn Kinneyofficer: CHIEF BUSINESS OFFICER | Option | 50,366 | $12.92 |
| Aug 6, 2026 | Horn Kinneyofficer: CHIEF BUSINESS OFFICER | Option | 40,250 | $10.60 |
| Aug 6, 2026 | Horn Kinneyofficer: CHIEF BUSINESS OFFICER | Sell | 90,616 | $25.09 |
| Jul 27, 2026 | Horn Kinneyofficer: CHIEF BUSINESS OFFICER | Grant | 31,250 | — |
| Jul 27, 2026 | Tsai Philipofficer: Chief Technical Officer | Grant | 38,250 | — |
| Jul 27, 2026 | Rosett Maxofficer: Chief Financial Officer | Grant | 94,500 | $22.01 |
| Jul 27, 2026 | Lechleider Robertofficer: Chief Medical Officer | Grant | 54,000 | — |
| Jul 27, 2026 | Lechleider Robertofficer: Chief Medical Officer | Grant | 108,000 | $22.01 |
| Jul 27, 2026 | SIEGALL CLAY Bdirector, officer: President and CEO | Grant | 180,000 | — |
| Jul 27, 2026 | SIEGALL CLAY Bdirector, officer: President and CEO | Grant | 360,000 | $22.01 |
Source: IMNM SEC Form 4 filings, latest Aug 12, 2026. For informational purposes only — not investment advice.
See the full IMNM insider & 13F page →Immunome, Inc. company profile
Overview
Immunome, Inc. (NASDAQ:IMNM) is a biopharmaceutical company founded in 2006 and headquartered in Exton, Pennsylvania. The company went public in October 2020 and focuses on discovering and developing antibody-based therapeutics for treating cancer and infectious diseases. Immunome leverages its proprietary antibody discovery platform to identify novel therapeutic targets and develop treatments that harness the immune system's power to fight disease.
Business
Immunome operates in the biotechnology sector, specifically in the field of antibody therapeutics development. The company's core business involves discovering, developing, and commercializing antibody-based drugs that can treat cancer and infectious diseases by modulating immune system responses. The company's primary focus areas include two main therapeutic segments. In oncology, Immunome develops IMM-ONC-01, an antibody therapy that targets IL-38, a tumor-derived immune checkpoint protein. IL-38 is a cytokine that tumors use to suppress the immune system and evade detection and destruction by immune cells. By blocking IL-38, IMM-ONC-01 aims to restore the immune system's ability to recognize and attack cancer cells, representing a novel approach to cancer immunotherapy. In infectious disease therapeutics, the company has developed IMM-BCP-01, an antibody cocktail specifically designed to treat SARS-CoV-2 infections and COVID-19. This treatment consists of multiple antibodies that work together to neutralize the coronavirus and prevent severe disease progression. Immunome's antibody discovery platform utilizes advanced technologies to identify human antibodies from memory B cells of individuals who have recovered from diseases or have been vaccinated. This approach allows the company to discover naturally occurring antibodies that have already proven effective in humans, potentially increasing the likelihood of therapeutic success and reducing development risks.
Revenue model
Immunome generates revenue primarily through collaboration agreements, licensing deals, and government contracts rather than product sales, as the company is still in the clinical development stage with no approved commercial products. The company's current revenue streams include research and development funding from partnerships with pharmaceutical companies, government agencies, and non-profit organizations. Based on recent financial data, the company generated approximately $9 million in revenue for fiscal year 2024, compared to $14 million in 2023, indicating fluctuating revenue tied to specific project milestones and contract deliverables. These revenues likely come from collaborative research agreements where partners pay for access to Immunome's antibody discovery platform and development expertise. The company's business model faces several margin-influencing factors. Positive factors include the high value potential of successful antibody therapeutics, which can command premium pricing due to their specificity and efficacy. The company's proprietary discovery platform could also generate recurring revenue through multiple partnerships and licensing agreements. However, negative factors significantly impact margins, including the high costs associated with clinical trials, regulatory compliance, and manufacturing scale-up. The biotechnology industry's inherently high failure rates mean substantial investments may not yield commercial returns. Additionally, competition from larger pharmaceutical companies with greater resources and established antibody platforms poses pricing pressure on partnership deals. The company's current pre-revenue status means it operates at negative margins, burning cash to fund research and development activities while building toward potential future profitability from successful drug approvals.
Competitive moat
Immunome's competitive moat appears relatively narrow in the highly competitive antibody therapeutics space. The company's primary differentiator lies in its proprietary antibody discovery platform that mines memory B cells from recovered patients, which could theoretically provide access to naturally validated antibodies with higher success probabilities than traditional discovery methods. However, this moat faces significant challenges. Large pharmaceutical companies like Roche, AbbVie, and Johnson & Johnson possess substantially greater resources, established manufacturing capabilities, extensive clinical trial networks, and regulatory expertise. These companies can acquire or license promising antibody technologies, potentially bypassing smaller players like Immunome. The antibody discovery field is also crowded with numerous platforms and technologies, including those from companies like Genmab, Seagen, and emerging biotechnology firms with novel approaches. The company's intellectual property portfolio and specific target identification capabilities may provide some protection, but the biotechnology industry's rapid pace of innovation means competitive advantages can erode quickly. Additionally, Immunome's dependence on partnership revenues rather than proprietary commercial products leaves it vulnerable to partner decisions and market consolidation. The company's small size and limited financial resources compared to industry giants further constrain its ability to compete in expensive areas like late-stage clinical trials and commercial manufacturing. While the company's approach shows promise, it operates in a space where technological moats are often temporary and success depends heavily on clinical trial outcomes and regulatory approvals.
Risks & safety
Immunome presents a mixed margin of safety profile typical of early-stage biotechnology companies, with strong liquidity but high cash burn rates. • Liquidity and Solvency: The company maintains a strong cash position with $257.6 million in cash and short-term investments as of Q1 2025, providing substantial runway. Current ratio of 10.5 and quick ratio of 10.5 indicate excellent short-term liquidity. Minimal debt with debt-to-equity ratio of only 0.016 eliminates solvency concerns. • Cash Burn Analysis: Free cash flow burn of approximately $57 million in Q1 2025 and $118 million for full year 2024 suggests current cash reserves could last approximately 4-5 years at current burn rates, though clinical trial progression typically increases expenses. • Valuation Metrics: Traditional valuation metrics are distorted due to pre-revenue status and negative earnings. Price-to-book ratio of 1.74 suggests reasonable valuation relative to tangible assets. Graham net-net value of 3.55 indicates the stock trades below liquidation value, providing some downside protection. • Other Considerations: Revenue volatility ($14M in 2023 vs $9M in 2024) indicates dependence on lumpy contract payments. High R&D intensity typical for biotechnology sector creates binary risk profile dependent on clinical trial outcomes.
Recent development
Based on available financial data, Immunome has been navigating the typical challenges of a clinical-stage biotechnology company over recent years. The company has maintained focus on advancing its two primary programs: IMM-ONC-01 for oncology applications and IMM-BCP-01 for COVID-19 treatment. The company's revenue patterns suggest ongoing partnership and collaboration activities, though with some volatility as revenues decreased from $14 million in 2023 to $9 million in 2024. This fluctuation is typical for companies dependent on milestone payments and research contracts rather than product sales. The company has maintained its research and development intensity, with significant cash burn rates indicating continued investment in clinical development programs. Immunome's financial position has been strengthened through what appears to be successful fundraising activities, as evidenced by the substantial increase in cash reserves from approximately $98 million at the end of 2023 to $257 million in Q1 2025. This capital infusion provides the company with extended runway to advance its clinical programs and potentially reach key development milestones. The company's operational focus appears to remain on progressing its antibody therapeutics through clinical trials while leveraging its discovery platform for potential additional partnerships and programs.
IMNM company profile · for informational purposes only — not investment advice.
Track IMNM with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free